Most colds are caused by rhinovirus infection, perhaps facilitated by chilling or stress. Virus infection begins in the nasopharynx and causes spotty destruction of the nasal ciliated epithelium. Transmission occurs chiefly via droplets of various sizes transported through the air, but some types of virus persist in moist secretions on handled objects and may retain their infectiousness. Living in crowded, poorly-ventilated quarters facilitates transmission. Not many virus particles survive in saliva and it is difficult to infect via the lips or mouth. Kissing does not efficiently spread cold infection. Prophylactic treatment with interferon does not protect against cold infection. Aspirin and acetaminophen reduced serum antibody response and increased nasal symptoms in a controlled Australian study. The combination of intranasal interferon and ipratropium with oral naproxen gave promising results in experimental rhinovirus inoculation. Basically, there has been little or no progress towards effective cold treatment in the past century.
Get full access to this article
View all access options for this article.
References
1.
TyrrellD.A.J.Hot news on the common cold. Ann Rev Microbiol1988; 42: 37–47.
2.
CrickF.H.C., WatsonJ.D.Structure of small viruses. nature1956; 177: 473–475.
3.
LevinR.M., GrossmanM.Group A streptococcal infection in children younger than three years of age. Pediatr Infect Dis J1988; 7(8): 581–587.
4.
GaribaldiR.A.Epidemiology of community-acquired respiratory tract infections in adults. Am Jour Med1985; 78(6B): 32–37.
5.
HendleyJ.O., GwaltneyJ.M.Mechanisms of transmission of rhinovirus infectious. Epidemiol Rev1988; 10: 243–258.
6.
HildingA.C.The common cold. Arch Otolaryng1930; 12: 133–150.
7.
PaulJ.H., FreeseH.L.An epidemiological and bacteriological study of the common cold in an isolated arctic community(Spitzbergen). Am Jour Hygiene1933; 17: 517–535.
8.
WarshauerD.M., DickE.C.Rhinovirus infections in an isolated Antarctica station. Am Jour Epid1989; 129: 319–340.
9.
WintherB., GwaltneyJ.M.Sites of rhinovirus recovery after point inoculation of the upper airway. JAMA1986; 256(13): 1763–1767.
10.
TurnerR.B., WintherB.Sites of virus recovery and antigen detection in epithelial cells during experimental rhinovirus infection. Acta Otolaryng Suppl1984; 413: 9–14.
MygindN., WintherB.Immunological barriers in the nose and paranasal sinuses. Acta Otolaryng1987; 103(5-6): 363–368.
13.
TurnerB.W., CailW.S.Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. Jour Allergy Clin Immunol1992; 90: 474–478.
14.
RautianenM., NuutinenJ.Ultrastructural changes in human nasal cilia caused by the common cold and recovery of ciliated epithelium. Ann Otol Rhin Laryngol1992; 101(12): 982–987.
15.
PedersenM., SakakuraY.Nasal mucociliary transport, number of ciliated cells, and beating pattern in naturally acquired common cold. Eur Jour Dis Suppl1983; 128: 355–365.
16.
WilsonR., AltonE.Upper respiratory tract viral infection and mucociliary clearance. Eur Jour Respir Dis1987; 70: 272–279.
17.
WintherB., BrofeldtS.Study of bacteria in the nasal cavity and nasopharynx during naturally acquired common colds. Acta Otolaryng1984; 98(3-4): 315–320.
18.
SmithA.P.Respiratory virus infections and performance. Philos Trans R Soc Lond Biol1990; 327(1241): 519–528.
19.
SauvageJ.P., OrselS., GuibbalJ.L.Value of local antibiotic therapy in respiratory tract infections. Rhinol Suppl1988; 5: 23–27.
20.
JenningsL.C., DickE.C.Near disappearance of rhinovirus along a fomite transmission chain. Jour Infect Dis1988; 158: 888–892.
21.
DickE.C., JenningsL.C.Aerosol transmission of rhinovirus colds. Jour Infect Dis1987; 156(3): 442–448.
22.
D'AllessioD.J., MechievitzC.K.Short-duration exposure and the transmission of rhinovirus colds. Jour Infect Dis1984; 150(2); 189–194.
23.
HaydenG.E., HendleyJ.O., GwaltneyJ.M.The effect of placebo and virucidal paper handkerchiefs on viral contamination of the hand and transmission of experimental rhinovirus infections. Jour Infect Dis1985; 152: 403–407.
24.
FarrB.M., HendleyJ.O.Two randomized controlled trials of virucidal nasal tissues in the prevention of natural upper respiratory infections. Am Jour Epid1988; 128: 1162–1172.
25.
GrahamD., HendersonF., HouseD.Neutrophil influx measured in nasal lavages of human exposed to ozone. Arch Environ Health1988; 43(3): 228–233.
26.
HendersonF.W., DuboviE.J., HarderS.Experimental rhinovirus infection in human volunteers exposed to ozone. Am Rev Respir Dis1988; 137(5); 1124–1128.
27.
HaydenF.G., GwaltneyJ.M.Prophylactic activity of intranasal enviroxime against experimentally induced rhinovirus type 39 infection. Antimicrob Agents Chemother1982; 21(6): 892–897.
28.
HaydenG.F., GwaltneyJ.M.Rhinovirus inactivation by nasal tissues treated with virucide. Antiviral Res.1985; 5(2): 103–109.
29.
FarrB.M., HendleyJoTwo randomized controlled trials of virucidal nasal tissues in the prevention of natural upper respiratory infections. Am Jour Epidemiol1988; 128(5): 1162–1172.
30.
DiehlH.S., BakerA.B., CowanD.W.Cold vaccines. An evaluation based on a controlled study. JAMA1938; 111: 1168–1173.
31.
ZerialA., WernerG.H.Studies on 44 0812 R.P., a new antirhinovirus compound, in cell cultures and in volunteers. Antimicrob Agents Chemother1985; 27(5); 846–850.
32.
SaitoH., TakenakaH.Prevention from naturally acquired viral respiratory infection by interferon nasal spray.1985; 23(4): 291–295.
33.
HigginsP.G., Al-NakibW.Interferon-beta ser as prophylaxis against experimental rhinovirus infection in volunteers. Jour Interferon Res1986; 6(2): 153–159.
34.
HigginsP.G., Al-NakibW.Recombinant human interferon-gamma as prophylaxis against rhinovirus colds in volunteers. Jour Interferon Res1988; 8(5): 591–596.
35.
FoyH.M., CooneyM.K.Influenza B in households: virus shedding without symptoms or antibody response. Am Jour Epidemiol1987; 126(3): 506–515.
36.
SperberS.J., LevineP.A.Ineffectiveness of recombinant interferon-beta serine nasal drops for prophylaxis of natural colds. Jour Infect Dis.1989; 160(4): 700–705.
37.
FarrB.M., GwaltneyJ.M.A randomized controlled trial of glucocorticord prophylaxis against experimental rhinovirus infection. Jour Infect Dis1990; 162(50): 1173–1177.
38.
ErnstE., PechoE.Regular sauna bathing and the incidence of common colds. Ann Med1990; 22(4): 225–227.
39.
AnsaiS.A., SpringthorpeV.S.Potential role of hands in the spread of respiratory viral infections; studies with human parainfluenza virus 3 and rhinovirus 14. Jour Clin Microbiol1991; 29(10): 2115–2119.
40.
HaydenF.G., AndriesK., JanssenP.A.Safety and efficacy of intranasal piodacir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother1992; 36(4): 727–732.
41.
PinnockC.B., GrahamN.M.Relationship between milk intake and mucus production if adult volunteers challenged with rhinovirus-2. Am Rev Respir Dis1990; 141(2): 352–356.
42.
CowanD.W., DiehlH.S.Antihistamine agents and ascorbic acid in the early treatment of the common cold. JAMA1950; 143: 421–424.
43.
HemilaH.Vitamin C and the common cold. Br Jour Nutr1992; 67(1): 3–16.
44.
GaffeyM.J., GwaltneyJ.M.Intranasally and orally administered antihistamine treatment of experimental rhinovirus colds. Am Rev Respir Dis1987; 136(3): 556–560.
45.
BerkowitzR.B., ConnellJ.T.The effectiveness of the nonsedating antihistamine loratadine plus pseudoephedrine in the symptomatic management of the common cold. Ann Allergy1989; 63(4): 336–339.
46.
GronborgH., WintherB.Effects of terfenadine in the treatment of common cold. A double-blind comparison with placebo. Eur Jour Clin Pharmacol1988; 34(1): 35–40.
47.
BrennerS., HodakE.A possible case of drug-induced familial pemphigus. Acta Derm Venereol1990; 70(4): 357–358.
48.
CurleyF.J., IrwinR.S.Cough and the common cold. Am Rev Respir Dis1988; 238(2): 305–311.
49.
HuttonN., WilsonM.H.Effectiveness of an antihistamine-decongestant combination for young children with the common cold: A randomized controlled clinical trial. Jour Pediatr1991; 118(1): 125–130.
50.
GrahamN.M., BurrellC.J.Adverse effects of aspirin, acetaminophen and ibuprofen on immune function, viral shedding, and clinical status in rhinovirus-infected volunteers. Jour Infect Dis1990; 162(6): 1277–1282.
51.
SmithM.B., FeldmanW.Over-the-counter medications. A critical review of clinical trials between 1950 and 1991. JAMA1993; 269(17): 2258–2263.
52.
HaydenF.G., GwaltneyJ.M.Intranasal interferon alpha 2 for the prevention of rhinovirus infection and illness. Jour Infect Dis1983; 148(3): 543–550.
53.
HaydenF.G., GwaltneyJ.M.Intranasal interferon-alpha 2 treatment of experimental rhinoviral colds. Jour Infect Dis1984; 150(2): 174–180.
54.
HaydenF.G., KaiserD.L., AlbrechtJ.K.Intranasal recombinant alpha-2b interferon treatment of naturally occurring common colds. Antimicrob Agents Chemother1988; 32(2): 224–230.
55.
HigginsP.G., BarrowG.I.Failure to demonstrate synergy between interferon-alpha and a synthetic antiviral, enviroxime, in rhinovirus infections in volunteers. Antiviral Res1988; 10(1-3): 14–149.
56.
GwaltneyJ.M.Combined antiviral and antimediator treatment of rhinovirus colds. Jour Infect Dis1992; 166(4): 776–782.
57.
PhillpottsR.J., WallaceJ.Therapeutic activity of enviroxine against rhinovirus in volunteers. Antimicrob Agents Chemother1983; 23(5): 671–675.
58.
EbyG.A., DavisD.R., HalcombW.W.Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study. Antimicrob Agents Chemother1984; 25(1): 20–24.
59.
WeismannK., JakobsenJ.P.Zinc gluconate lozenges for common colds, a double-blind clinical trial. Dan Med Bull1990; 37(3): 279–281.
60.
TyrellD., BarrowI., ArthurJ.Local hyperthermia benefits natural and experimental common colds. BMJ1989; 298(6683): 1280–1283.
61.
MackninM.L., MathewS., MedendorpS.V.Effects of inhaling heated vapor on symptoms of the common cold. JAMA1990; 264(8): 989–991.
